ImmuPharma PLC
Full ImmuPharma PLC profile hereImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. Its wholly owned subsidiaries include ImmuPharma (UK) Limited, which is a holding company; ImmuPharma (France) SA, which is engaged in pharmaceutical research and development, and ImmuPharma AG, which is engaged in pharmaceutical research and development.
Manish Singh, President & CEO of ImmunoCellular Therapeutics, talks about targeting cancer stem cells
Manish Singh, President & CEO of ImmunoCellular Therapeutics, talks about targeting cancer stem cells – which are like the roots of cancers, 40% of glioblastoma patients (from a Phase 1 trial) being cancer free after 3-4 years & a platform for delivering cancer stem cell antigens for multiple different indications (July 2011).



















